Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: FEBS J. 2021 Dec 1;289(9):2613–2627. doi: 10.1111/febs.16291

Figure 6. Effect of UBIAD1 mutations on MK-4 biosynthesis.

Figure 6

(A and B) UBIAD1 or its variants was transiently expressed in UBIAD1-deficient FIXgla-PC/HEK293 reporter cells. Transfected cells were incubated with a cell culture medium containing 1 μM COT-vitamin K for 24 hours. K vitamins were extracted from the treated cells for the conventional HPLC assay. Pure MK-4 and MK-4 epoxide were used as standards to define the retention time of these compounds in the HPLC chromatogram. (C) MK-4 biosynthetic activity of UBIAD1 and its variants were determined from peak areas of MK-4 and MK-4 epoxide in Figure 6A and 6B. Wild-type UBIAD1 activity was normalized to 100%. Data are presented as mean ± SD of three independent experiments (n=3). * T-test, P<0.01, compared with the wild-type UBIAD1 (WT).